Asparenomycin A, a new carbapenem antibiotic. 1981

K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D002627 Chemistry, Physical The study of CHEMICAL PHENOMENA and processes in terms of the underlying PHYSICAL PHENOMENA and processes. Physical Chemistry,Chemistries, Physical,Physical Chemistries
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D013302 Streptomyces A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.
D013845 Thienamycins Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors. Antibiotics, Thienamycin,Thienamycin Antibiotics
D047090 beta-Lactams Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria. beta-Lactam,4-Thia-1-Azabicyclo(3.2.0)Heptanes,4-Thia-1-Azabicyclo(4.2.0)Octanes,beta Lactam,beta Lactams
D055598 Chemical Phenomena The composition, structure, conformation, and properties of atoms and molecules, and their reaction and interaction processes. Chemical Concepts,Chemical Processes,Physical Chemistry Concepts,Physical Chemistry Processes,Physicochemical Concepts,Physicochemical Phenomena,Physicochemical Processes,Chemical Phenomenon,Chemical Process,Physical Chemistry Phenomena,Physical Chemistry Process,Physicochemical Phenomenon,Physicochemical Process,Chemical Concept,Chemistry Process, Physical,Chemistry Processes, Physical,Concept, Chemical,Concept, Physical Chemistry,Concept, Physicochemical,Concepts, Chemical,Concepts, Physical Chemistry,Concepts, Physicochemical,Phenomena, Chemical,Phenomena, Physical Chemistry,Phenomena, Physicochemical,Phenomenon, Chemical,Phenomenon, Physicochemical,Physical Chemistry Concept,Physicochemical Concept,Process, Chemical,Process, Physical Chemistry,Process, Physicochemical,Processes, Chemical,Processes, Physical Chemistry,Processes, Physicochemical
D065093 beta-Lactamase Inhibitors Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. beta Lactamase Inhibitor,beta Lactamase Inhibitors,beta-Lactamase Inhibitor,beta Lactamase Antagonists,Antagonists, beta Lactamase,Inhibitor, beta Lactamase,Inhibitor, beta-Lactamase,Inhibitors, beta Lactamase,Inhibitors, beta-Lactamase,Lactamase Antagonists, beta,Lactamase Inhibitor, beta,Lactamase Inhibitors, beta

Related Publications

K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
December 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
January 1997, Pharmacotherapy,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
May 1988, The Medical clinics of North America,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
September 1982, The Journal of antibiotics,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
February 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
December 2005, The Japanese journal of antibiotics,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
August 1997, The Journal of antimicrobial chemotherapy,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
May 1993, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
December 1986, Minnesota medicine,
K Tanaka, and J Shoji, and Y Terui, and N Tsuji, and E Kondo, and M Mayama, and Y Kawamura, and T Hattori, and K Matsumoto, and T Yoshida
January 1986, Giornale di batteriologia, virologia ed immunologia,
Copied contents to your clipboard!